JP2017522277A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522277A5
JP2017522277A5 JP2016570862A JP2016570862A JP2017522277A5 JP 2017522277 A5 JP2017522277 A5 JP 2017522277A5 JP 2016570862 A JP2016570862 A JP 2016570862A JP 2016570862 A JP2016570862 A JP 2016570862A JP 2017522277 A5 JP2017522277 A5 JP 2017522277A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016570862A
Other languages
English (en)
Japanese (ja)
Other versions
JP6552061B2 (ja
JP2017522277A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/034964 external-priority patent/WO2015191630A1/en
Publication of JP2017522277A publication Critical patent/JP2017522277A/ja
Publication of JP2017522277A5 publication Critical patent/JP2017522277A5/ja
Application granted granted Critical
Publication of JP6552061B2 publication Critical patent/JP6552061B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016570862A 2014-06-10 2015-06-09 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用 Active JP6552061B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009910P 2014-06-10 2014-06-10
US62/009,910 2014-06-10
PCT/US2015/034964 WO2015191630A1 (en) 2014-06-10 2015-06-09 Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof

Publications (3)

Publication Number Publication Date
JP2017522277A JP2017522277A (ja) 2017-08-10
JP2017522277A5 true JP2017522277A5 (enExample) 2018-07-19
JP6552061B2 JP6552061B2 (ja) 2019-07-31

Family

ID=54834213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016570862A Active JP6552061B2 (ja) 2014-06-10 2015-06-09 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用

Country Status (6)

Country Link
US (4) US9969726B2 (enExample)
EP (1) EP3154954B1 (enExample)
JP (1) JP6552061B2 (enExample)
AU (1) AU2015274781C1 (enExample)
CA (1) CA2950952C (enExample)
WO (1) WO2015191630A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10099993B2 (en) * 2014-04-06 2018-10-16 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof
AU2015274781C1 (en) 2014-06-10 2019-08-08 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
MA41562B1 (fr) 2015-06-03 2019-05-31 Bristol Myers Squibb Co Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
CN108299303B (zh) * 2018-02-09 2022-10-11 中山大学 一种四芳基吡唑类化合物的合成新方法
CN108997325B (zh) * 2018-07-06 2020-08-04 浙江工业大学 一种芳基联噻唑类化合物和应用
CA3145507A1 (en) * 2018-07-27 2020-01-30 Daniel Pierce RADIN Clinical methods and pharmaceutical compositions employing ampa receptor antagonists to treat glioblastoma and other cancers
US12366579B2 (en) * 2019-03-21 2025-07-22 University Of Virginia Patent Foundation Sulfur-heterocycle exchange chemistry and uses thereof
CN110183382A (zh) * 2019-06-06 2019-08-30 东北师范大学 新型三氟甲基吡唑类化合物合成方法
CA3148435A1 (en) * 2019-07-22 2021-01-28 Angion Biomedica Corp. Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors
JPWO2021117759A1 (enExample) 2019-12-10 2021-06-17
JP2023541153A (ja) * 2020-09-14 2023-09-28 ジェンザイム・コーポレーション 鎌状赤血球症を処置するための、ビスホスホグリセリン酸ムターゼのモジュレーターとしてのカルボン酸含有化合物
CN112480073B (zh) * 2020-12-02 2022-03-22 武汉药明康德新药开发有限公司 1-烷基-3,5-芳基取代的1,2,4三氮唑化合物的合成方法
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
CN116041277B (zh) * 2023-01-18 2024-11-01 中国药科大学 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用
US11970460B1 (en) 2023-10-24 2024-04-30 King Faisal University 4-(4,5-bis(4-bromophenyl)-2-phenyl-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1224174E (pt) 1999-10-15 2004-01-30 Hoffmann La Roche Derivados de benzodiazepina como antagonistas do receptor metabotropico do glutamato
CA2386980C (en) 1999-10-15 2010-03-16 Geo Adam Benzodiazepine derivatives for use in acute or chronic neurological disorders
ES2292830T3 (es) * 2001-02-21 2008-03-16 Astrazeneca Ab Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
ES2235044T3 (es) 2001-04-12 2005-07-01 F. Hoffmann-La Roche Ag Derivados de dihidro-benzo (b) (1,4)-diazepin-2-ona como antagonistas i de mglur2.
ES2246012T3 (es) * 2001-04-12 2006-02-01 F. Hoffmann-La Roche Ag Derivados de dihidro benzo(b) (1,4)diacepin-2-ona como antagonistas de mglur2 ii.
EP1392684B1 (en) * 2001-06-01 2006-09-13 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinases
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
EP1485093B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
BR0317430A (pt) * 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
JP2006522128A (ja) * 2003-04-03 2006-09-28 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体−5のモジュレーターとしての4環イミダゾール誘導体
CA2532505A1 (en) * 2003-07-24 2005-02-10 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
EP1753428A4 (en) * 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
JP5244589B2 (ja) * 2005-06-27 2013-07-24 エグゼリクシス パテント カンパニー エルエルシー イミダゾールに基づくlxrモジュレーター
EP2001849B1 (en) 2006-03-29 2014-11-26 F. Hoffmann-La Roche AG Pyridine and pyrimidine derivatives as mglur2 antagonists
US8012986B2 (en) * 2007-04-02 2011-09-06 Hoffmann-La Roche Inc. Pyridine and pyrimidine derivatives as MGLUR2 antagonists
EP2145873A1 (fr) * 2008-06-17 2010-01-20 Commissariat A L'energie Atomique Nouveaux composés ayant une activité protectrice vis-à-vis de l'action de toxines et de virus au mode d'action intracellulaire
BR112012013199A8 (pt) 2009-12-14 2018-01-02 Msd Oss Bv Composto, composição farmacêutica, e , uso de um composto
WO2011116356A2 (en) * 2010-03-19 2011-09-22 Sanford-Burnham Medical Research Institute Positive allosteric modulators of group ii mglurs
EP2751095B1 (en) 2011-08-29 2021-10-27 Sanford-Burnham Medical Research Institute Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
AU2015274781C1 (en) 2014-06-10 2019-08-08 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof

Similar Documents

Publication Publication Date Title
JP2017522277A5 (enExample)
JP2019524883A5 (enExample)
JP2013519675A5 (enExample)
JP2015516427A5 (enExample)
JP2013509429A5 (enExample)
JP2013032389A5 (enExample)
JP2014506907A5 (enExample)
JP2019516739A5 (enExample)
JP2020532547A5 (enExample)
JP2012144574A5 (enExample)
JP2015537008A5 (enExample)
JP2014508811A5 (enExample)
JP2014511891A5 (enExample)
JP2014508753A5 (enExample)
JP2015024998A5 (enExample)
JP2017514910A5 (enExample)
JP2013518107A5 (enExample)
JP2018510138A5 (enExample)
JP2014507455A5 (enExample)
JP2017509689A5 (enExample)
JP2015508092A5 (enExample)
JP2019520344A5 (enExample)
JP2014507477A5 (enExample)
EA201070783A1 (ru) 1,2,4-оксадизольные соединения для лечения аутоиммунных заболеваний
JP2016510326A5 (enExample)